Evaluation of IL 12B Genetic Polymorphism (rs3213094) in Patient With Psoriasis and Psoriatic Arthritis in Response to Humira

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales. The disease can also impair the eyes and joints. It has no cure. Because of their low quality of life, many psoriasis patients experience depression. In addition to the cutaneous manifestations, it is associated with an increased risk of psoriatic arthritis, depression and cardiovascular disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: t
View:

• \- Patients having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of severe, defined as a Psoriasis Area and Severity Index (PASI) score greater than 10, and involvement of greater than 10% of the body surface area (BSA) with psoriatic arthritis.

Locations
Other Locations
Egypt
Qina University hospital, South Valley University Hospital
RECRUITING
Qina
Contact Information
Primary
Alaa Ahmed Saad Ali Aweida, MSc
alaaahmed201666@gmail.com
+201119814470
Backup
Soheir Abdel-Hamid Ali, Lecturer
Soher.abdel-hamed@med.svu.edu.eg
+201066877343
Time Frame
Start Date: 2025-08-01
Estimated Completion Date: 2026-02-01
Participants
Target number of participants: 40
Treatments
Active_comparator: Patients Group
About 20 patients with psoriasis and psoriatic arthritis.
Active_comparator: Healthy Group
About 20 healthy control group.
Related Therapeutic Areas
Sponsors
Leads: South Valley University

This content was sourced from clinicaltrials.gov